1
项与 Cyclin B1/WT-1/CEF peptide-loaded dendritic cell vaccine(Baylor Scott & White Research Institute (BSWRI)) 相关的临床试验Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
The secondary objectives of this trial are to determine pathologic complete response rates; disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients receiving DC vaccinations; and to assess the feasibility of immunizing LA TNBC and ER+/HER2- BC patients with patient-specific tumor antigens.
100 项与 Cyclin B1/WT-1/CEF peptide-loaded dendritic cell vaccine(Baylor Scott & White Research Institute (BSWRI)) 相关的临床结果
100 项与 Cyclin B1/WT-1/CEF peptide-loaded dendritic cell vaccine(Baylor Scott & White Research Institute (BSWRI)) 相关的转化医学
100 项与 Cyclin B1/WT-1/CEF peptide-loaded dendritic cell vaccine(Baylor Scott & White Research Institute (BSWRI)) 相关的专利(医药)
100 项与 Cyclin B1/WT-1/CEF peptide-loaded dendritic cell vaccine(Baylor Scott & White Research Institute (BSWRI)) 相关的药物交易